We are pleased to announce that we successfully integrated a Plasminogen module into the WAPPS-Hemo website, including the following features:
- Addition of a dedicated Population PK model describing the PK of Ryplazim®, a Plasminogen concentrate recently approved by the FDA for the treatment of plasminogen-deficiency type 1. The model was developed from 16 Plasminogen Deficient patients from 4 to 42 years with a median of 21 and evaluated for Bayesian forecasting (Figure 1).
- Addition of the Disease: Plasminogen Deficiency when creating new patients (Figure 2).
- Display of relevant PK outcomes for Plasminogen Deficient Patients in both the PK Estimate and Clinical Calculator features.
For detailed information regarding the Plasminogen Deficiency and its treatment, you can look up the Partners in Bleeding Disorders Education website.
We hope that real world experience through data gathered via this new module will help in advancing understanding and treatment of this rare disorder.